- Home
- EGY vs CRVS Comparison
EGY vs CRVS Comparison
Compare EGY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EGY | CRVS |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.9M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | EGY | CRVS |
|---|---|---|
| Price | $3.46 | $7.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 884.7K | ★ 1.6M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $389,951,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.53 | N/A |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $2.54 |
| 52 Week High | $4.82 | $9.60 |
Technical Indicators
Market Signals| Indicator | EGY | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 44.45 |
| Support Level | $3.41 | $7.34 |
| Resistance Level | $3.59 | $8.00 |
| Average True Range (ATR) | 0.09 | 0.52 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 36.36 | 18.42 |
Price Performance
Historical ComparisonAbout EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).